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Abstract 
To determine the effectiveness of punctal occlusion for the treatment 
of dry eye. Fifteen subjects with signs and symptoms of dry eye had 
dissolvable collagen punctal plugs inserted into the superior and inferior 
puncta of both eyes. Subjectively, all the subjects felt that occlusion 
alleviated some of the dry eye symptoms they were experiencing. Marked 
improvement of fluorescein corneal staining and the Schirmer's test also 
improved during occlusion. These results suggest co11agen puncta I occlusion 
is an effective diagnostic test to help determine which dry eye patients 
would benefit from a more permanent type of occlusion. 
Introduction 
Pat1ents with dry eye conditions are commonly seen 1n optometric 
practices. It has been ranked as the ntnth most prevalent self-reported 
health problem, just beh1ng ang1na and chronic bronchitis'. An assessment 
of the type and degree of dry eye must be made tn order to adopt the most 
appropriate management strategy. Proper education must also be employed 
in order to prevent any inordinate expectations and ensure compliance as the 
treatment is usually long term. Most dry eye conditions cannot be cured, 
therefore measures need to be taken to protect the cornea 1 and conjunct iva 1 
epithelium and provide symptomatic relief. Artificial tears provide the 
primary treatment for patients w1th aqueous deficiencies. Packaging is 
convenient and can be instilled at the patients discretion. A supplemental 
ointment can also be applied at bedtime. At times when the patient is 
elderly, physically impaired, has occupational restrictions or current 
treatment 1s not successful wtth art1f1c1aJ tears an altemat1ve moda11ty 
must be sought•. One such altemattve, the occluston of the tacrtmat puncta, 
should be considered. This method slows down or prevents tear Joss thus 
providing a reservoir of tears for the cornea. 
Permanent puncta! occlusion is done by cauterization or surgical 
suture. Many optometric practitioners avoid these procedures because they 
are nonreversible and symptoms can persist2. The cauterized puncta can 
also reopen and return and possible worsening of original symptoms may 
occurl. Moreover, too much tear pooling might occur and excess fluid can 
lead to epiphora which may require additional surgery for correction". 
Alternatively, silicone plugs can be permanently implanted. Silicone plug 
instillation is a much more tolerated procedure and can be done on an 
outpatient basis in your office. The plugs have the potential for being 
removed at some future date if the need arises. Patients are much more 
comfortable with silicone plugs as they don't view this as a "surgicar 
alternative. These advantages, along with the poss1b11ity that the patient's 
medical insurance will cover the cost of the procedure, make silicone 
puncta! plug occlusion for the management of aqueous deficient dry eye a 
viable working alternative. The disadvantages are that the patient may 
experience a foreign body sensation or the plugs may accidentally dislodge. 
When the advantages outweigh the disadvantages permanent puncta! 
occlusion must be given serious consideration. To diagnosticatly test the 
efficacy of permanent punctal occlusion, dissolvable collagen plugs can be 
utilized. By assessing the signs and symptoms before and after collagen 
use, a more informed decision can be made when making the final 
determination for permanent occlusion. This project will investigate the 
efficacy of puncta! occlusion for alleviating dry eye signs and symptoms. 
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Subjects 
All subjects were drawn from the general population to ensure a 
homogenous base. This was accompHshed by placing an announcement in the 
local newspaper and by posting notices at Pacific University College of 
Optometry Family Vision Center cHnics in Portland and Forest GroveJ 
Oregon. Acceptable candidates were those with a previous diagnosis of dry 
eye or these with experiencing the most common symptoms of dry eye: 
bumingJ soreness~ dryness and grittiness. Prior to the initial appointment~ 
subjects were given a detailed project overview. The purpose~ goalsJ 
benefits and risk factors were explained. Once these and the time 
commitment was fully understood and accepted~ they were al1owed in the 
study. 
The subject's ages ranged from twenty-two to e1ghty-four. Dry eye 
affects v1rtually all ages. Therefore 1t must be kept 1n m1nd that dry eye 1s 
not spectftc to any age groupJ such as ger1atr1c. It 1s perttnent to ment1on 
that contact lens wearers were purposely excluded. This was done to test 
specifically the effects of punctal occlusion on dry eye in general. 
Additional investigation of the efficacy of punctal occlusion for contact 
lens patients with dry eye should be undertaken. 
Those with gross abnormalities of the lidsJ conjunctiva or cornea 
along with any current infections such as blepharitis or allergic 
conjunctivitis were not included in the study. These subjects are not 
compatible with a study of this sort and would adversely effect the data. 
Test sequence 
Three v1s1ts were requtred by each parttctpant. At the 1n1tta1 vtsit a 
careful h1story was obta1ned to ascertatn whether or not the1r symptoms 
were caused by extrinsic factors such as allergies, medications, 
environmental conditions and various other circumstances that may cause 
dry eye. It was important to monitor these factors throughout the study so 
that any change, either positive or negative, would not be wrongfully 
attributed to the collagen plugs. Often times your patient aren't aware of or 
don't reaHy give consideration to the thought of modifying their work and 
home environment to ease their chronic dry eye symptoms. While keeping 
this in mind the practitioner may have the opportunity to give their patient 
needed advice as to constructive modification of their work or home 
conditions. Additionally, the subjects were instructed to continue their 
normal daily activities. 
Punctal plugs were instilled on the first visit. According to the 
manufacturer, the collagen plugs dissolve in seven to ten days following 
instillation. A second v1sit was scheduled three days later and a third visit 
ten days after inst111ation to assess both signs and symptoms at the mid-
point and end of their duration, respectively. 
Subjective assessment 
Upon the 1n1t1al v1s1t a deta11ed explanation of the project was given 
to all participants. This included a project overview, number and length of 
each required visit and informed consent. Any questions or concerns were 
addressed at this time. A preprinted subjective evaluation form was 
completed at the beginning of each of the three required visits(Fig 1 ). They 
were asked to rate the four most common symptoms of dry eye, burning, 
soreness, dryness and grittiness according to the frequency and severity for 
each eye. A scale of 0 to 4 was used for the frequency with 0 as having 
experiencing none, 1 if not everyday, 2 as having these symptoms a few 
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hours a day, 3 for most of the day and 4 when 1t occurred all day long. 
Severity was also rated on a scale of o to 4 with 0 being none, 1 for just 
noticeable, 2·as mlld, 3 when moderate and 4 if it was virtually intolerable. 
For each visit the frequency score was multiplied by the severity score to 
derive a total score for that symptom. By staying with four of the most 
common symptoms, rather than presenting everyone with an entire list of 
all the possible problems one could experience when having dry eye, 
individual interpretation variabllities between each subject would be held 
to a minimum. Using a scale of 0 to 4 also controlled the variances in 
response as to the frequency and severity. Often times one has completely a 
different interpretation of how bad or good something is compared to the 
next person and by keeping the choices confined it would give us more 
consistent results. 
Subjects were also asked whether or not they suffered from 
conditions such as asthma, hay fever, heart problems, or simllar medical 
diseases. Any or all of these systemic conditions can have an effect on dry 
eye either directly or indirectly. If the subjects were taking any 
medications or were using eye drops they were to note this as well. Often 
times medications can be the culprit for the cause of dry eye. This is 
important as you would not want to permanently occlude the puncta when 
the medication was only temporary as normal tear flow would be expected 
at the termination of medical therapy. Any sensitivity to bright Hghts, 
smoke, dust, fumes and other such obnoxious insults were asked to be noted. 
If there is a possibility to modify the environment, either at home or work, 
this could be much easier than treating the effects causing the problem. 
Many patients tn the office wi11 complain of betng sens1ttve to smoke, 
especially that from cigarettes. They need to rea11ze that tf they are 
5 
wllling to change some habits, they can help themselves, but until then you 
may be able to provide pa111attve treatment. Patient education ts paramount 
when manag1ng any type of condition be it contact lenses, low vision, vision 
therapy, glaucoma or dry eye. If this ts kept in mind, the successful 
practitioner will maintain rapport with her patient and have better 
compliance over the long term. 
Objective Assessment(Fig 2) 
At the beginning of the study visual acuities were taken at distance 
and near for each person. Sometimes overlooked on routine examination, 
visual acuity can be depressed secondary to dry eye. With the help of an 
ointment at night or artificial tears during the day, tt may be enough to 
alleviate symptoms and help acuity in certain instances. Although this was 
not assessed statistically during the study tt could be considered tn the 
future. 
The blink rate was measured by counting the number of blinks over a 
thirty second period and doubllng this figure for a per minute rate. This was 
done casually while conversing with the patient. Often times a patient is 
unaware of their blink habits. This is particularly so when their work 
involves a computer. It has been shown that bltnk rate decreases over time 
when viewing a computer terminal versus reading printed materialt3. Any 
partlat or incomplete blinking was recorded. Patients such as these seen tn 
your office can be helped by instructing them to "think blink!". They can post 
a creative looking note in a conspicuous place reminding them to take full 
complete blinks and more of them. 
A non-anesthetized (Jones' •n Schirmer's test was performed using 
the standard technique. This was done prior to the biomicroscopy 
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examination to prevent any artiflcial effects such as reflex tearing which 
would be caused by the bright llght. The Jones· •1 was chosen over the 
Jones· •2 as-this has been shown to be the more reproducible method giving 
the most accurate results•o. The Schirmer's strip was placed lightly on the 
temporal third of the lower lld being careful not to touch the cornea or 
bulbar conjunctiva. By instructing them to look superiorly and nasa11y this 
prevented any chance of touching the cornea or the globe. Both eyes were 
tested simultaneously. After flve minutes the length of tear fllm 
saturation of the strip was measured. 
A careful slit-lamp examination was performed next. The integrity of 
the llds, lashes, conjunctiva, cornea and tear fllm were evaluated. Any 
abnormallties of these structures such as trichiasis, entropian, meibom1an 
gland dysfunction and simllar possibllities were carefully recorded and then 
fluorescein was inst11led. Using a single appllcation of a Ful-Glo strip, wet 
with ster11e saline, a slight amount was applied to the superior bulbar 
conjunctiva wh11e the patient looked inferiorly. Again the aforementioned 
structures were evaluated. Corneal staining with fluorescein was graded on 
a scale of 0 to 4 with 0 being no observed staining, I as m11d, 2 for 
moderate, 3 when large patches of coalesced staining was seen and 4 if 
severe staining with epithelial erosion were present. Figures 3-a,b,c & d 
were used as a basis for comparison to maintain consistency in grading. 
Pooling, stipple staining, tear debris, foreign body tracking or other similar 
observations were noted as well. 
The tear break-up time (TBUT) was then establlshed. This was 
accomplished by taking and averaging three consecutive measures for each 
eye. The subject was instructed to take a full b11nk and refra1n from 
b11nk1ng. A narrow three m1111meter parallelop1ped was used to v1ew the 
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Figure 3a 
grade 1 mild 
Figure 3b 
grade 2 moderate 
Figure 3c 
grade 3 large patches of 
coalesced staining 
Figure 3d 
grade 4 severe, corneal 
epithelial erosions 
Figure 4a 
grade 1 mild 
Figure 4b 
grade 2 moderate 
Figure 4c 
grade 3 severe· 
fluorescein stained tear film while silently counting the seconds until the 
tear fi1m became compromisedJO. Any loss of the tear film integrity, 
signified by a black spot tn the green fluorescein, was deemed the endpoint 
for determining the tear break up time. Using a narrowed beam allows you 
to view the tear film adequately whereas a full beam has the potential of 
drying the tear film prematurely thus giving a shortened breakup time. After 
taking the reading on one eye, the other eye was assessed, alternating from 
eye to eye until three concurrent readings were obtained for each eye. 
Rose Bengal stain, which stains devitalized tissue, is paramount 
when attempting a dry eye workup. Rose Bengal single applicatlon sterile 
strips, moistened with sterile saline solution, were used. The subjects 
were instructed to took superiorly white the end of the steri te strip was 
touched to the inside tower lid taking care not to touch neither the 
conjunctiva nor the cornea. This step of the procedure is quite important 
because you could have a pseudostain caused by tracking from the strip due 
to poor application technique. It was necessary to place several drops of 
saline on the strip to obtain enough solution for adequate staining. Future 
studies should use the one percent solution that is available in convenient 
five mi11i1iter bottles. This is a more viable alternative as this gives you 
enough stain to make a reliable assessment and you don't have to use 
multiple applications which is common if you use the strips. The solution 
would also eliminate the possibility of pseudostain when using the strip. 
Upon immediate instillation of the stain it is good to note whether or not 
the subject experienced any pain. Pain is often a confident indicator of a 
positive dry eye. 
Staining was graded on a scale of 0 to 3 for both the temporal and 
nasal conjunctiva along with the cornea. A grading of 0 indicated no 
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staining was noted~ 1 meant m11d staining was observed, 2 for moderate and 
when severe amounts were seen a grade of 3 was assigned. Figures 4-a, b 
and c were used for comparison when grading Rose Bengal staining to 
maintain consistency. 
Collagen Plug Insertion 
Once the subjective and objective evaluation was completed on the 
initial visit it was time to place the plugs in all four puncta. Collagen plugs 
were obtained from Eagle Vision which are available in diameters of .2, .3 
and .4 millimeters. It is well to note here that collagen plugs can be 
purchased by companies other than Eagle Vision and that the named company 
did not supply the plugs at no charge. All of the plugs were on the average 
of two millimeters in length. The available punctal plug sizes w111 
generally fit all punctal sizes. The choice of plug diameter is made when 
doing the biomicroscopy exam at which time you can gauge the size of plug 
deemed adequate for that sub jeers puncta. 
Some advocate the use of a dilator prior to the instillation of the 
collagen plugs. This enlarges the puncta to allow easier insertion of the 
plugs or some may argue that you do this to enable the use of a larger 
diameter plug. It was found that dilation was not necessary for two 
reasons. First after dilation it is necessary to set down the dilator quickly 
and grasp the plug the plug with the forceps for immediate insertion as the 
puncta will constrict rather rapidly. Once you are proficient with the 
technique it will be easier to incorporate the use of the dilator. However, 
unless you are in a practice where you are placing a lot of plugs, it would be 
fruitless to dilate for the placement of collagen plugs. Another reason for 
not us1ng a d11ator 1s that the plugs absorb water immediately after 
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insertion and swell thus securing themselves. You can usually choose a 
large enough diameter plug without the need for dilation. 
When placing the permanent silicone plugs, it is necessary to dilate 
the puncta. This dilation step is made easier by the applicator that is 
supplied wlth the sillcone plugs. On one end of the applicator is the dilator 
and the other is a holder for the plug. Once you have the puncta dilated you 
can readily switch ends of the applicator and immediately place the plug 
with minimal constriction. A patient in the study elected to have silicone 
plugs placed and in this case it is necessary to dilate the puncta as you 
want the largest possible plug so as to prevent dislodging. 
Patients were counseled to possibly expect a sllght probing sensation 
as the plug went in, but that in all likelihood they would not feel any 
sensation at all. One drop of O.SX proparacaine solution was placed in each 
eye prior to the procedure to decrease the bUnk reflex. The pattent was 
placed in the Fowler position and made comfortable. With their head tipped 
back s11ghtly the subjects were asked to look inferiorly and temporal when 
placing the superior puncta and look superiorly and temporal when placing 
the inferior ones. This technique aided the application making the puncta 
more readily accessible and decreased the possibility of injury to the 
subject. The plugs were grasped with a jeweler's forcep about one-third of 
the way from one end. The plug was grasped in this manner so that the 
longer end would be available to placed in the puncta first. Once the plug 
was introduced into the puncta the pressure was released from the forceps, 
turned sideways and the ttp was used to push the remainder of the plug 
down into the puncta. The plug was in position when the proximal end was 
recessed slightly into the puncta. Once proper placement was achieved the 
forceps were maintained on the puncta for approximately one minute to 
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insure the uptake of fluid fnto the plug which allowed 1t to swell. It was 
found that tf the patient was allowed to close their eyes and bllnk a few 
times immediately after insertion the freshly inserted plug would be 
blinked out. By taking this extra step in the procedure you can eliminate the 
frustration and waste of using another plug. 
After all of the plugs were instilled, the subjects were instructed not 
to rub their eyes in the vicinity of the puncta. This was done to prevent the 
inadvertent dislodging of the plug. Subjects were also counseled as to the 
expectation of a slight foreign body sensation that they might experience 
which would be normal. 
Statistical Analysis 
Statistical analysts of the data was done using the Stat View-S 12+11 
program and Macintosh computers. Due to the nature of the data, both non-
parametric and parametric analyses were required. Non-parametric 
measurements included grading systems such as rose bengal staining and 
subjective grading of symptoms such as dryness or burning. Parametric 
data included Schirmer's test and b11nk rate. 
For the non-parametric data the Friedmann statistical program was 
used to determine if there was a significant difference in the findings 
between visits. Of those findings whose Chi corrected values were above 
5.99 the Wllcoxon signed-rank program was subsequently used to evaluate 
significant differences between visits 1 and 2, visits 1 and 3 and visits 2 
and 3. Of those significant Friedmann 3 group tests a WiJcoxon signed-rank 
test was done to establish significance between individual visits. Any 
corrected Z value of 1.65 or more tndtcated a stattsttcally stgntftcant 
change. 
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For parametric statistical analysis the one factor AUJVA statistical 
program (with a significance level of 90% using mean difference), Fisher 
PLSD, Dunnett-t and Scheffe F-tests were used. 
Results 
A significant difference was appreciated in all subjective findings 
except soreness, which was rated low by patients to begin with and 
remained low at the end of the study. On the complaint of dryness, a 
statistically significant improvement was made on all visits. A change was 
seen from visit 1 to 2, from visit 1 to 3 and visit 2 to 3. With grittiness, a 
difference was perceived from visit 1 to 2 and visit 1 to 3, but not between 
visit 2 to 3. The reason for non-significance between visits 2 to 3 is that 
the grittiness findings improved greatly between visit 1 to 2 and remained 
low through the third visit. With subjecttve bumtng ftndtngs we ftnd the 
exact same relationship. First, a highly stgntftcant change between vtsit 1 
to 2 and between vis1t 1 to 3, but no real change between visit 2 to 3, but 
again w1th further evaluation of the data, one sees a drop in the subjective 
ranking of burning that remained low through the third visit. 
Subjective findings save soreness were all at the 90% significant 
level between visit 1 to 2 and visit 1 to 3 with the Fisher PLSD and Scheffe 
F-test results. A change in soreness symptoms did reach the 90~ 
significant level with Fisher PLSD results between visit I to 3. 
Of the objective tests, fluorescein staining and the Schirmer's strip 
were the only objective findings that were significantly different between 
visits. An improvement of the staining did not occur between visit 1 to 2, 
but was seen between visit 2 to 3 with an even higher overall improvement 
seen between vtstt 1 to 3. Schtrmer's testing tndtcated an overall 
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significant change between visit 1 to 3 as with fluorescein staining, but 
unlike the staining the major change was seen between visit 2 to 3. The 
blink rate findings also achieved a 90~ significance level between visit 1 to 
3, which means that the differences of the findings were high enough to 
indicate statistically valid change from visit to visit. TBUT remained 
steady throughout the study. 
Discussion 
Clearly, punctal occlusion must be given consideration when managing 
your dry eye patients. This is indicated by the fact that all subjects 
experienced improvement with the objective findings showing similar 
results. 
Subjective improvement is very important as the patient needs to 
experience the improvement in order to proceed with permanent occlusion. 
Once this has been demonstrated and the patient is willing to commit to a 
permanent therapy alternative, silicone plugs should be instilled. 
Objective findings followed what was expected. Fluorescein staining 
and Schirmer's test results indicated a significant marked improvement 
towards alleviation of dry eye signs. The fluorescein stain findings did not 
show improvement on the second visit three days after occlusion, however 
with additional time, improvement was observed ten days after occlusion on 
visit 3. These changes could result from the fact that tissue physiology and 
morphology changes require additional time to be noticed. 
The opposite is true for the Schirmer's test as significant changes 
did occur three days after occlusion. This indicates that aqueous volume 
increased initially rather quickly and then remained stable throughout the 
rest of the study. 
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Approximately half of the fifteen patients that completed the study 
believed the procedure helped them enough to want to discuss the 
possib111ty of permanent occlusion. One participant went so far as to have 
the silicone plugs placed by us. Three and six month follow-up examinations 
on the subject have shown continued favorable results. Another benefit to 
the collagen plug trial is that the patients can readily make the decision 
themselves when deciding on permanent occlusion. They will have 
experienced the benefits first hand which places the final decision in their 
hands. Those who felt that permanent occlusion wasn't necessary indicated 
that they would continue their current methods of therapy. These included 
artificial tears, ointment at night, long time inserts such as Lacriserts or a 
combination of the above. Permanent occlusion will cost the patient 
between $300-500 which is a factor for some. For these reasons and the 
probability that their dry eye problem isn't a nuisance the use of artificial 
tears on a periodic basis is more practical. 
To reiterate what has been uncovered in this study one must note 
that an increase in the aqueous volume lent to a decrease in symptoms and 
an improvement in the physiologic signs of dry eye. 
A significant change in mucin layer was not expected and likewise no 
changes were found. This was indicated by the lack of change in the TBUT 
results. The break up time is an indication of the mucin layer integrity and 
shouldn't be affected by aqueous volume changes. 
Punctal occlusion did not change the Rose Bengal stain and blink rate 
findings which remained constant throughout the study. 
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Figure 1 
SUBJECfiVE SYMPTOM EVALUATION FORM 
N AME ________________________________ AGE _______ SEX _______ D ATE ______ _ 
ADDRESS-------------------------------------------------------------
0 C CUP A TI ON-----------------------------------------------PHONE ____ _ 
Please rate the frequency and severity of the following symptoms using the scale that 
follows . Do this for each eye. Circle the corresponding number that applies. 
Frequency: O=none, l=not every day, 2=a few hours per day, 3=most but not all of the day, 
4=all day long, constant. 
Severity: O=none, l=just noticeable, tolerable, 2=mild, 3=moderate, 4=severe, intolerable 
BURNING: 
SORENESS: 
DRYNESS: 
GRITTINESS: 
Have you had 
*ALLERGIES 
*ARTHRITIS 
*ASTHMA 
*HEADACHE 
FREQUENCY SEVERITY 
RIGHT EYE __ LEFT EYE.....__RIGHT EYE...._LEFT EYL_ 
RIGHT EYE __ LEFT EYIL__RIGHT EYE...._LEFT E~ 
RIGHT EYE __ LEFT EYE.....__RIGHT EYE...._LEFT E~ 
RIGHT EYL_LEFT EYIL__RIGHT EYE...._LEFf E~ 
or currently have any of the following: (circle the ones that apply) 
*BRONCHITIS *EYE INFECfiONStrRAUMA *HAY FEVER 
*COUGH (CHRONIC) *EAR TROUBLE *POST-NASAL DRIP 
*DIABETES *GLAUCOMA *HEART PROBLEMS 
*EYE SECREI10NS *SKIN CONDmONS *CONT ACf LENSES 
*NASAL PROBLEMS *'IHYROID PROBLEMS 
*OTHEE-----------------------------------------------------------NOTES, ________________________________________________________ __ 
Arc you currently taking any of the following medications: (circle the ones that apply) 
• ANTIHISTAMINES (cold medication) *MEDICATION FOR illGH BLOOD PRESSURE 
*ORAL CONTRACEPTIVES *MEDICATION FOR DIGESTIVE PROBLEMS 
*SLEEPING TABLETS *EYE DROPS 
*DIURETICS (water pills) *OTHER _________________________ _ 
NOTES. ____________________________________________________ __ 
Are you senstuve to any of the following 
*CIGARETTE SMOKE I FUMES I SMOG 
*HOT AIR VENTS 
conditions: (check the ones that apply) 
• AIR CONDmONER 
*BRIGHT UGHTS NOTES, _________________________________________________ ___ 
Nrume ____________ _ 
FAR 
Figure 2 
OBJECTIVE EVALUATION . 
Date ________ __ 
NEAR 
OD __ _/ ___ _ ____ / -----
OS __ _/__ _ ____ / ____ _ 
ou __ _/ ________ / ____ _ 
SLE before fluorescein; 15 mag, 3mm wide parallelopiped, low illumination. 
*CORNEA *CONJUNCTIVA *LIDS *DEBRIS *TRICHIASIS 
*PUNCTA *LID EVERSION *BLINK FUNCTION *STRUCTURAL 
*ABNORMALITIES 
E XPLAN A TI 0 N ------------------------------------------------------------
BLINK RATE (30 SECONDS) _____ _ 
FLUORESCEIN EVALUATION 15 mag, 3mm wide parallclopiped, medium illumination with 
cobalt blue filter and yellow Wratten filter. Place one drop of sterile unpreserved saline 
on the fluorescein strip and touch the superior temporal bulbar conjunctiva once with the 
moistened strip. Evaluate the following: 
OD (PICTURE) OS (PICTURE) 
TBUT (two full blinks prior to measurement, 3 trials) 
on __ ; _______ _ OS _____________ _ 
DEGREE OF CORNEAL STAINING: (GRADING BASED ON COMPARISON WITH 
PHOTOGRAPHS) O=CLEAR, l=MILD, 2=MODERA TE, 3=LARGE PATCHES OF COALESCED 
STAINING, 4=SEVERE, CORNEAL EPITHELIAL EROSIONS 
OD OS ____ _ 
ROSE BENGAL (MEDIAL AND LATERAL CONJUNCTIVA AND CORNEA) O=CLEAR, l=Mll..D, 
2=MODERATE, 3=SEVERE 
OD (PICTURE) OS (PICTURE) 
SCHIRMER (number of mm wet in 5 minutes) Use a Whatman No. 46 filter paper, 5mm X 
30mm bent 5mm from each end. Place in lower lid of each eye. 
OD OS __ _ 
RWorksheet 1 
V3-GRIT -SCORE V 1-BLINK V2-BLI NK V3-BLINK V1-RB-SUM V2-RB-SUM V3-RB-SUM V1-FLUO-SUM 
0 40 28 10 0 3 0 0 
4 0 3 0 0 
0 5 6 5 0 0 0 0 
0 0 0 0 0 
0 6 20 20 2.01 2 1 0 
0 0 2 1 0 
9 10 10 NA 2.01 0 1 6 
1 2.01 1 1 6 
0 20 18 19 2.01 2 0 3 
6 2.01 2 0 3 
0 14 19 9 2.01 0 0 6 
0 3.99 1 0 6 
0 17 17 9 0 1 0 6 
0 0 1 1 6 
0 8 11 14 8.01 6 3 6 
0 8.01 6 3 6 
0 16 1 0 13 0 1 2 0 
0 0 1 2 3 
1 22 15 14 0 1 0 0 
1 0 1 0 6 · 
0 26 18 22 3 0 0 3 
0 3 3 3 3 
0 24 18 10 2.01 0 0 3 
0 2.01 0 0 3 
1 35 16 18 0.99 0 2 3 
1 0.99 1 2 3 
1 24 19 23 0 0 0 0 
1 0.99 1 0 0 
0 20 20 20 0 1 0 0 
0 0.99 0 0 0 
o-? 
RWorksheet 1 
V2-FLUO-SUM V3-FLUO-SUM V 1-SCHI RM V2-SCHIRM V3-SCHIRM V 1-TBUT -AVE V2-TBUT -AVE V3-TBUT -AVE 
3 3 18 23 22 
3 3 10 21 26 
3 0 22 30 30 
3 0 30 30 35 
0 0 4 5 7 
0 0 5 6 4 
3 3 2 1 1 
3 0 4 4 5 
3 3 13 2 5 
3 3 7 3 2 
0 3 35 5 13 
0 6 13 6 13 
3 3 35 30 20 
6 3 35 30 20 
3 3 15 17 14 
3 3 35 19 24 
3 0 35 12 18 
3 0 35 12 14 
3 3 30 22 30 
3 0 30 26 25 
0 3 35 30 30 
0 3 35 30 30 
6 0 18 12 14 
6 0 14 9 10 
3 0 35 30 22 
3 0 35 30 30 
3 0 35 30 30 
3 0 35 30 30 
0 0 30 30 35 
0 0 30 30 35 
o-~ 
0 
0 
21.3 
25 
5 
7.67 
7.67 
9.67 
8.3 
3.33 
9 
5 
0 
8.33 
3.67 
2 
0 
0 
3 
9.67 
12.33 
11.33 
5 
2.67 
12.67 
23.67 
18.67 
22.67 
5 
4.67 
3 
4 
6 
4.6 
3 
2.33 
5.67 
5.67 
3.33 
3 
12.33 
15.33 
12.67 
12 
2.33 
2 
2.33 
3 
5.33 
5 
9.33 
15 
3 
5 
14.67 
7.33 
12.33 
13 
I 0 
8.33 
4.6 
4.6 
7.6 
6 
4 
3.33 
5.33 
6 
7.33 
7.67 
6.67 
8.67 
3.33 
5.33 
5.67 
8 
8.33 
10.33 
6.67 
17.67 
9.67 
9 
11 
14.33 
8.67 
8.67 
23 
24.33 
5 
8 
RWor ksheet 1 
V1-SORE-SCORE V2-SORE-SCORE V3-SORE-SCORE V1-DRY-SCORE V2-DRY-SCORE V3-DRY-SCORE 
0 0 0 4 0 0 
0 0 0 12 1 4 
0 0 0 2 1 1 
0 0 0 6 4 4 
0 0 0 6 2 6 
0 0 0 0 0 0 
4 2 6 9 4 9 
1 0 1 2 1 4 
2 3 0 16 0 4 
2 6 4 4 9 12 
0 0 0 8 4 2 
0 0 0 8 4 2 
9 0 0 12 2 0 
9 0 0 12 2 0 
0 0 0 0 0 0 
8 0 0 8 0 0 
0 0 0 4 0 0 
0 0 0 4 0 0 
0 0 0 2 2 6 
0 0 0 2 2 6 
1 0 0 4 2 1 
1 0 0 4 2 I 
0 0 0 1 1 I 
0 0 0 4 3 2 
6 9 6 9 1 4 
6 12 6 9 1 4 
0 0 0 6 1 2 
0 0 0 6 1 2 
1 4 1 4 1 0 
1 4 1 6 1 0 
o-.4 
~treJEC"l'!n rnmrno nAn 
• NON-PARAMEm!C 
Friedman 3 X variables 
CF 2 
# Samples 3 
#Cases l3o 
Chir·Squared 20.6 
Chi corrected for ties 25.224 , 
# tied grouos , 3 [7 
Friedman 3 X variables 
Name: I. Rank : Mean Rank : 
V1 -DRY -SCORE 80 2.667 
V2-DRY -SCORE 47 1.567 
V3-DRY -SCORE 53 , . 767 2 
[7 
Friedman 3 X variables 
CF 2 
#Samples 3 
#Cases 30 
Chir·Squared , 1.667 
Chi corrected for ties 20 1 
I tied groups 23 [7 
Friedman 3 X variables 
Name: !. Rank: Mean Rank: 
V1·GRIT·SCORE 75 2.5 
V2-GRIT -SCORE 50 1.667 
V3·GRIT·SCORE 55 1.833 2 
[7 
Friedman 3 X varlablea 
[F 2 
I Samples 3 
I Cases 30 
Chir·Squared 21.217 
Chi corrected for ties 33.065 1 
I tied groups 16 7 
Friedman 3 X variables 
Name: I. Rank: Mean Rank: 
V1 -BURN-SCORE 80 .5 2.683 
V2-BURN-SCORE 48 1.6 
V3-BURN-SCORE 51.5 1. 717 2 
7 
Friedman 3 X variables 
[F 2 
I Samples 3 
#Cases 30 
Chir·Squared .817 
Chi corrected for ties 2.333 1 
II tied groups 27 7 
Friedman 3 X variables 
Name: £Rank: Mean Rank: 
V1-SORE-SCORE 62 .5 2.083 
V2-SORE-SCORE 61.5 2.05 
V3-SORE-SCORE 56 1.867 2 
v 
Wilcoxon algned-rank X1: V1-DRY-SCORE Y1: V2-DRY-SCORE 
Number: L Rank: Mean Rank: 
- Ranks ~1.;__-------+1..:.1-=6-------11...:1...::6::..... _____ --l 
+ Ranks ~...;2;;..4 _______ ...... ..;;.3..;;.0....;;9 ______ ..J...:1..:2;.;.· ;;..8.:..7;;..5 ____ .....J 
note 5 cases eliminated for difference • 0. 
z -3.942 
Z corrected for ties -3 .954 
# tied groups 6 
Wilcoxon signed-rank X1: V1-DRY-SCORE Y1: V3-DRY-SCORE 
Number: L Rank: Mean Rank: 
- Ranks ~~4:...,_ _____ ~~~4;..::5:::...._ _____ f.:.1..:..1.:..:·2:.:5:::...._ ___ ~ 
+ Ranks L.:2:...1~------..J..:2:.::B:.::O:._ ____ ..L..:.1 ;:;..3.:.;:3:.::3:.::3;..._ __ ~ 
note 5 cases eliminated for difference • 0. 
z -3 .162 
Z corrected for ties -3 .176 
# tied orouos 7 
Wilcoxon algned-rank X1: V2-DRY-SCORE Y1: V3-DRY-SCORE 
Number: I. Rank: Mean Rank: 
• Ranks ~1_2;;;;..... _______ ,1-
5
1;...;7
8
_;3;._... _____ 4,...:.1...:.4..:...4.:..1:....:7;..._ __ ~ 
+Ranks 9 6.444 ~------~~------~~~----~ 
note 9 cases eliminated for difference .. 0. 
z -1.999 
Z corrected for ties -2.013 
I tied groups 4 
Wilcoxon algned-rank X1: V1-GRIT-SCORE Y1: V2-GRIT-SCORE 
Number: I. Rank: Mean Rank : 
- Ranks ~1.:.__------t=-2:..:. 5:...._------+1-=2.:....: 5:...._ ____ -l 
+ Ranks L.1.:...8;..._ _____ ...... ...;.1~8..:...7.:....:.5:....... ____ -...~....;1....:::0;..:. ....;.4..:...1 .:...7 ____ ___..~ 
note 11 cases eliminated for difference • 0. 
z -3 .722 
Z corrected for ties -3.76 
t1 tied groups 3 
Wilcoxon algned-rank X1: V1-GRIT-SCORE 
- Ranks 
+Ranks 
Number: 
4 
17 
r Rank: 
29.5 
201.5 
note 9 cases eliminated for difference .. 0. 
z -2.989 
Z corrected for ties -3 .011 
# tied oroups 5 
Wilcoxon algned-rank X1: V2-GRIT-SCORE 
Y1: V3-GRIT-SCORE 
Mean Rank: 
7.375 
11.853 
Y1: V3-GRIT-SCORE 
Number: I. Rank: Mean Rank: 
- Ranks ~6;..._ _____ _,,r-::2:...:5;..:.·.;;.5 _____ --+,....;.4..:..:2::..:5:....... ____ --l 
+ Ranks 3 19 .5 6 .5 ~-------~~:.......-----~~------~ 
note 21 cases eliminated for difference .. 0. 
z - .355 
Z corrected for ties - .362 
I tied oroups 2 
Wilcoxon algned-rank X1: V1-BURN-SCORE Y1: V2-BURN-SCORE 
Number: I. Rank: Mean Rank: 
- Ranks ,..,_:O::...._ ______ t.;;..o _______ ;,-· _______ -1 
+ Ranks L.:2::..1..:...._ _____ • .=.2.;;..3...;.1 ______ _....;1_1~--------' 
note 9 cases eliminated for difference • 0. 
z -4 . 01 5 
Z corrected for ties -4 .027 
# tied groups 6 
Wilcoxon signed-rank X1: V1-BURN-SCORE Y1: V3-BURN-SCORE 
Number: I. Rank: Mean Rank: 
- Ranks ~o::...._ ______ t.;;..o _______ ~l-·-------~ 
+ Ranks L.:2=-0=--_____ ___,~o..;;2;..;1...;;0~-----..&....;.1.;;.0..;.;. 5::...._ ___ ___. 
note 1 0 cases eliminated for difference • 0. 
z -3 .92 
Z corrected for ties -3.94 
I tied groups 3 
Wilcoxon algned-rank X1: V2-BURN-SCORE Y1: V3-BURN-SCORE 
Number: I. Rank: Mean Rank: 
- Ranks ~9;;...._ _____ -4,_
4
7_
9
1 _______ t...;7_.8;..;8;..;9'--------t 
+ Ranks L. 6=---------..&.  ...;..;;.--------'·o..;;8..;. . .:..16;:;.7..:...._ ___ ___. 
note 15 cases eliminated for difference • 0. 
z -.625 
Z corrected for ties -.676 
I tied grouos 1 
PARAM?I'RIC 
One Factor ANOVA-Repeated Mea au rea for X1 ••• X3 
Source: df: Sum of Squares: Mean Square: F-test: P value: 
Between subjects 29 368 .9 12.721 1.084 .3861 
Within subjects 60 704 11 .733 
treatments 2 276.867 138 .433 18.798 .0001 
res idual 58 427.133 7.364 
Total 89 , 072 .9 
Rel iabil ity Estimates for- All treatments : .078 Single Treatment: .027 1 [7 
One Factor ANOVA-Repeated Measures for X1 .•. XJ 
Group: Count : Mean: Std . Dev.: Std . Error: 
V 1 -DRY -SCORE 30 5.8 3.89 . 71 
V2-DRY -SCORE 30 1.733 1.874 .342 
V3-DRY -SCORE 30 2.567 2.967 .542 
2 
7 
One Factor ANOVA-Repeated Measures for X1 .•• X3 
Comparison: Mean Diff. : Fisher PLSD: Scheffe F -test : Dunnett t: 
V1 -DRY-SC .. . VS . V2-DRY ... 4.067 1.171* 1 6.842* 5.804 
V1 ·DRY -SC ... VS. V3-DRY ... 3 .233 1.171* 10.64 7* 4.615 
V2-DRY-SC .. . vs. V3-DRY ... - .833 1 .171 .707 1.189 
• Significant at 90% 
3 
7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Source· df: Sum of Squares: Mean Square: F-test: P value· 
Between subjects 29 395.156 13.626 3 .797 .0001 
Within subjects 60 215 .333 3.589 
treatments 2 11 .356 5 .678 1.614 .2078 
residual 58 203.978 3.517 
Total 89 610.489 
Reliabi lity Estimates for- All treatments: . 737 Single Treatment: .482 
One Factor ANOVA-Repeated Measures for X1 ... X3 
Group: Count: Mean: Std. Dev.: Std. Error: 
Vl-SORE-SCORE 3 0 1.7 2.879 .526 
V2-SORE-SCORE 3 0 1.333 2.952 .539 
V3-SORE-SCORE 3 0 .833 1.913 .349 
2 
[7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comparison : Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
Vl-SORE-S .. . vs. V2-SOR ... .367 .809 .287 .757 
V1-SORE-S ... vs. V3-SOR .. . .867 .809* 1.602 1.79 
V2-SORE-S ... vs. V3-SOR ... .5 .809 .533 1.033 
• Significant at 90% 
3 
[7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Source: df: Sum of Squares: Mean Square: F-test: P value: 
Between subjects 29 467.122 16.1 08 2.831 .0003 
Within subjects 60 341 .333 5.689 
treatments 2 87 .222 43.611 9.954 .0002 
residual 58 254.111 4 .381 
Total 89 808 .456 
Reliability Estimates for- All treatments: .647 Single Treatment: .379 
1 
[7 
One Factor ANOVA-Repeated Measures for X1 ••. X3 
Group : Count : Mean: Std. Dev.: Std. Error: 
V1 -GRIT-SCORE 30 2.867 4.15 .758 
V2-GRIT-SCORE 3 0 .7 1.896 .346 
V3-GRIT -SCORE 3 0 .867 2.013 .367 
2 
[7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comparison: Mean Diff.: F is her PL SD: Scheffe F -test: D unnett t: 
V1 -GRIT-S ... vs. V2-GRIT ... 2.167 . 903. 8 . 036. 4.009 
V1-GRIT·S ... vs. V3-GRIT ... 2 . 903. 6.B4r 3. 701 
V2-GRIT-S ... vs. V3-GRIT ... -.167 .903 .048 .308 
• Significant at 90% 
3 
One Factor ANOV A-Repeated Measures ~or x1 ••. XJ 
Source : df: Sum of Squares: Mean Square: F-test: P value: 
Between subjects 29 171 .556 15.916 1.036 .4416 
With in subjects 60 342 .667 Is. 111 
treatments 2 150.022 175.011 22 .584 .0001 
residual 58 192.644 13 .321 
Total 89 514.222 I 
Reliabili ty Estimates for- All trea!ments : .035 Single Treatment: .012 1 
[7 
One Factor ANOVA-Repeatad Measures for X1 •. . X3 
Group: Count: Mean : Std . Dev. : Std . Error: 
V1-BURN-SCORE 30 3 .267 3 .258 .595 
V2-BURN-SCORE 30 .433 .679 .124 
V3-BURN·SCORE 30 .633 1.217 .222 
2 
[7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
V1-8URN-S ... vs. V2-BUR. .. 2.833 . 787" 18 . 127* 6.021 
V1-BURN-S ... vs. V3-BUR. .. 2.633 . 787* 1 5.658* 5.596 
V2-BURN-S ... vs. V3-BUR. .. -. 2 .787 .09 .425 
• Significant at 90% 
3 
7 
OBJ!C'"n't"! !'INDINO !TATS 
NON-PARAM!'ImC 
Friedman 3 X varlablea 
CF 2 
#Samples 3 
#Cases 30 
Chir·Squared 9.517 
Chi corrected for ties 10.673 
# tied groups 13 
Friedman 3 X variables 
Name: r Rank: Mean Rank: 
V1-SCHIRM 73 2.433 
V2-SCHIRM 49 .5 1.65 
V3-SCHIRM 57 .5 1.917 
Friedman 3 X variables 
CF 2 
I Samples 3 
#Cases 30 
Chlr·Squared 4.517 
Chi corrected for ties 7.039 
I tied groups 25 
Friedman 3 X variables 
Name: 'r. Rank: Mean Rank: 
V1-FLUO-SUM 65 2.167 
V2-FLUO-SUM 64.5 2.15 
V3-FLUO-SUM 50 .5 1.683 
2 
7 
1 [7 
2 
7 
Friedman 3 X variable• 
a= 2 
#Samples 3 
#Casas 30 
Chir·Squared 3.65 
Chi corrected for ties 4.813 1 
# tied groups 1 7 [7 
Friedman 3 X variables 
Name: I. Rank: Mean Rank: 
V1-RB-SUM 65 2.167 
V2-RB-SUM 63 .5 2.117 
V3-RB-SUM 51 .5 , . 717 2 
7 
Friedman 3 X varlablea 
a= 2 
I Samples 3 
II Cases 30 
Chir·Squared 3.317 
Chi corrected for ties 3.373 1 
II tied groups 2 [7 
Friedman 3 X variables 
Name: r Rank: Mean Rank: 
V1 -TBUT-AVE 59 1.967 
V2-TBUT-AVE 53.5 1.783 
V3-TBUT-AVE 67.5 2.25 2 
7 
Friedman 3 X variables 
Cf 2 
#Samples 3 
#Cases 15 
Chir·Squared 4.633 
Chi corrected for ties 5 .346 1 
# tied groups 5 [7 Note: 15 cases dele!ed with missing values. 
Friedman 3 X variables 
Name: I Rank : Mean Rank : 
V1-BLINK 36 .5 2.433 
V2-BLINK 28 .5 1. 9 
V3-8LINK 25 1.667 2 
[7 
Table 2 . 
X1: AGE 
Mean : Std . Dev.: St.d . Error : 
ls3 121.031 ls.43 
Minimum: Maximum: Range : 
122 I les 163 
Wilcoxon algned-rank X1: V1-SCHIRM Y1: V2-SCHIRM 
Number: I Rank: Mean Rank: 
-Ranu ~~6~------------t~6~0.~5~---------t~1~0~. 0~8~3--------~ 
+ Ranks ...,;2;;..0;;.._ _____ .,.~,..=2..;;9..;;0..:.;. 5:;._ ____ __._..,;1~4:..:.· ~5=-2~5 ____ ___. 
note 4 cases eliminated for difference • 0. 
z -2.921 
Z corrected for ties -2.941 
t tied groups 6 
Wilcoxon algned-rank X1: V1-SCHIRM v,: V3-SCHIRM 
Number: I Rank: Mean Rank: 
- Ranks 18 
+ Ranks20 
199.5 
:306.5 
112.438 
15 .325 I 
note 2 cases eliminated for difference • 0. 
z -2.357 
Z corrected for ties -2.371 
t tied arouos 5 
Wilcoxon signed-rank X1: V2-SCHIRM v,: V3-SCHIRM 
Number: I Rank: Mean Rank: 
- Ranks 115 1:~· 112.267 I +Ranks 8 1 1 .5 
note 7 cases eliminated for difference ,. 0. 
z _, .399 
Z corrected for ties -, .404 
t tied Qroups 6 
Wilcoxon algned-rank X1: V1-FLUO-SUM Y1: V2-FLUO-SUM 
Number: !: Rank: Mean Rank: 
_ Ranks ~,~o=--------rg::...;s=-------~1.:..9..:..:. s=-------4 
+ Ranks L.. 1.:...:...0 _______ .J....:..1 ...:.1.:..5 ______ .....1..1.:...:..1 ·:.:S:;_ _____ ...J 
note 1 0 cases eliminated for difference • 0. 
z - .373 
Z corrected for ties - . 41 
# tied qroups 2 
Wilcoxon algned-rank X1: V1-FLUO-SUM 
- Ranks 
+Ranks 
Number: 
3 
13 
r Rank: 
22.5 
113.5 
note 14 cases eliminated for difference • 0. 
z -2 .353 
Z corrected for ties -2.556 
# tied qroups 2 
Wilcoxon algned-rank X 1 : V2-FLUO-SUM 
Y1: V3-FLUO-SUM 
Mean Rank: 
7.5 
8.731 
Y1: V3-FLUO-SUM 
Number: !: Rank: Mean Rank: 
- Ranks ~4..;.._ ______ r3;..;s;..;·..;;;.s _____ ....,.l..;;;.9..:..;. 6:.:2::;.:s:__ ___ -~ 
+ Ranks ._1.;...3.;._._ _____ ,_1.;...1.;...4.;..;·..;;;.5 _____ ....~._..;;;.8.:..:. 8::...;0;..;8:__ ___ .....J 
note 13 cases eliminated for difference = 0. 
z -1 .799 
Z corrected for ties -1 .927 
I tied qroups 2 
PARAM!'lmc 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Source: df: Sum of Squares· Mean Square: F-test: P value: 
Between subjects 29 9532.489 328 .707 9.47 .0001 
Within subjects 60 2082.667 34.711 
treatments 2 422.022 211.011 7.37 .0014 
res idual 58 1660.644 28 .632 
Total 89 11615 .156 
Reliabil ity Estimates for- All treatments: .8.94 Single Treatment: .738 
One Factor ANOVA-Repeated Measures for X1 ... X3 
Group: Count: Mean : Std. Dev.: Std . Error: 
V1-SCHIRM 30 23 .833 12. 12 2 .213 
V2-SCHIRM 30 18.833 11.148 2.035 
V3-SCHIRM 30 19.8 10.714 1.956 
2 
[7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comparison : Mean Diff.: Fisher PLSD: Scheffe F-test : Dunnett t: 
V1·SCHIRM VS . V2-SCHIRM 5 2. 31. 6.549. 3 .619 
V1-SCHIRM VS. V3-SCHIRM 4.033 2 . 31. 4.261. 2.919 
V2-SCHIRM VS. V3-SCHIRM -. 967 2 .31 .245 .7 
• Significant at 90% 
3 
[7 
One Factor ANOVA-Repeated Meaaures for X1 ••• X3 
Source: df: Sum of Squares· Mean Square: F-test: P value· 
Between subjects 29 1615.319 55.701 2.476 .0015 
Within subjects 60 1350.028 22.5 
treatments 2 41.66 20.83 .923 .4029 
residual 58 1308.368 22.558 
Total 89 2965.347 
Reliability Estimates for- All treatments: .596 Single Treatment: .33 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Grouo· Count· Mean· Std Dev · .. Std Error· 
Vt -TBUT-AVE 30 8.243 7.415 1.354 
V2-TBUT -AVE 30 7.03 4.443 .811 
V3-TBUT-AVE 30 8.627 5.109 .933 
2 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comoarison : Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
Vt-TBUT- ... vs. V2-TBUT ... 1.213 2 .05 .489 .989 
V1-TBUT- ... vs. V3-TBUT ... -.384 2.05 .049 .313 
V2-TBUT- ... vs. V3-TBUT ... -1.596 2.05 .847 1.302 
3 
7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Source: df: Sum of Squares: Mean Square: F-test: P value: 
Between subjects 1 4 1465.467 104.676 2.649 .0123 
Within subjects 30 1 185.333 39.511 
treatments 2 218.8 109.4 3.169 .0574 
residual 28 966 .533 34 .519 
Total 44 2650.8 
Reliability Estimates for- All treatments: .623 Single Treatment: .355 
Note: 15 cases deleted with missing values. 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Group: Count : Mean: Std. Dev.: Std. Error: 
V1-BLINK 1 5 1 9 .133 10.042 2.593 
V2-BLINK 1 5 16.333 5.367 1.386 
V3-BLINK 1 5 13.733 6.638 1.714 
2 [7 
One Factor ANOVA-Repeated Measures for X1 ••• X3 
Comparison : Mean Diff. : Fisher PLSD: Scheffe F -test : Dunnett t: 
V1-BLINK vs. V2-BLINK 2.8 3.65 .852 1.305 
V1-BLJNK VS. V3-BLINK 5.4 3. 65" 3.168" 2.517 
V2-BLINK vs. V3-BLINK 2.6 3.65 .734 1.212 
• Significant at 90% 
3 
[7 
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